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Résumé 
Introduction 
Le neuroblastome (NB) est la tumeur maligne solide extra-crânienne la plus fréquente chez l'enfant. 
Sa présentation clinique est très hétérogène, allant d'une tumeur localisée à une atteinte métastatique 
sévère. Malgré des traitements agressifs, environ 55% des NB de hauts risques sont actuellement 
résistants aux thérapies. L'espoir réside dans le développement de traitements ciblant les mécanismes 
moléculaires responsables du développement et de la progression du NB. Le gène Anaplastie 
Lymphoma Kinase (ALK) codant pour un récepteur tyrosine kinase a été particulièrement étudié ces 
dernières années car il est muté, amplifié ou surexprimé dans une majorité des NBs. Le but de ce 
projet était d'investiguer le rôle de ALK-wt, ainsi que de ces deux plus fréquentes mutations, ALK-
F ll 74L et ALK-R1245Q, dans !'oncogenèse du NB. Le NB étant originaire des cellules de la crête 
neurale, nous avons analysé le potentiel oncogénique de ces différentes formes de ALK dans des 
cellules progénitrices de la crête neurale (NCPC). 
Méthode 
Des NCPC de souris (JoMal), possédant un c-MycER inductible pour leur maintien en culture in 
vitro, ont été transduites par un rétrovirus permettant l'expression stable de ALK-wt, ALK-F1174L et 
ALK-R1245Q. Des tests in vitro ont d'abord été effectués pour tester le système c-MycER, la stabilité 
de nos cellules transduites, leur phénotype, leur capacité de croissance et leur tumorigénicité. Les 
cellules transduites ont ensuite été injectées dans des souris immunosupprimées en sous-cutané, puis 
en orthotopique, c'est-à-dire dans leur glande surrénale, afin de mesurer leur tumorigenicité in vivo. 
Résultats 
La transduction et l'expression stable de ALK n'ont pas modifié le phénotype indifférencié des 
JoMal, ni de manière significative la capacité de croissance des cellules in vitro en absence 
d'activation de c-MycER. Par contre, lorsque c-MycER est actif, les cellules porteuses des mutations 
FI l 74L et R1245Q ont montré une meilleure capacité de prolifération et de formation de colonies, par 
rapport aux JoMal-ALK-wt et aux cellules contrôles en culture 3D dans de la méthylcellulose et dans 
un test de formation de neurosphères. ln vivo, les souris injectées avec les cellules JoMa1-ALK-
Fl 174L en sous-cutané ou dans la glande surrénale ont rapidement développé des tumeurs, suivies par 
le groupe JoMal-ALK-Rl245Q et le groupe JoMal-ALK-wt, alors que les groupes de souris contrôles 
n'ont présenté aucune tumeur. En orthotopique, nous avons obtenu 5/6 tumeurs ALK-Fl 174L, 7/7 
tumeurs ALK-Rl245Q et 617 tumeurs ALK-wt. Les tumeurs sous-cutanées ne présentaient pas de 
différences morphologiques et histologiques entre les différents groupes et montraient une histologie 
compatible avec un NB. Les tumeurs orthotopiques restent encore à analyser. 
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Conclusion 
Cette étude a permis de démontrer que les mutations activatrices F 1174L et RI 245Q ont des propriétés 
tumorigéniques in vitro dans des NCPC et in vivo tandis que la forme sauvage de ALK montre une 
capacité oncogénique uniquement in vivo. Bien que la caractérisation des tumeurs orthotopiques n'a 
pas encore été effectuée, l'analyse des tumeurs sous-cutanées nous suggère que l'expression de ALK-
wt ou muté est suffisante pour induire la formation de NB à partir des cellules progénitrices de la crête 
neurale. Le gène ALK semble donc jouer un rôle important dans l'oncogénèse du NB, aussi bien par la 
présence de mutations activatrices que par sa fréquente surexpression. 
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Introduction 
Neuroblastoma 
Neural crest cells are a transient population of neuroectodermal pluripotent cells in vertebrate 
embryon. During their anterior or posterior neural migration, they differentiate to give rise to various 
mature cell types as neurons, glial cells, melanocytes, chondrocytes, bone cells, myofibroblasts, 
adipocytes and endocrine cells [1, 2], as illustrated in Figure 1. Neuroblastoma (NB) is an embryonal 
tumor derived from neural crest progenitor cells (NCPC) [3] involved in the sympathetic nervous 
system development [4]. 
Cranlal Trunk 
Nature Revlews I 
« Neural crest cells rnigrate througl1out the body and differentiate into rnany different cell types Althougll neural crest 
cells are pluripotent, differences exist between cells tllat are generated from different anteroposterior lev els: neural 
crest cells in tl1e trunk form m elanocytes and several neuron and glia cell types, whereas neural crest cells in the 
cranial (the embryonic head region) also have the potential to form mesencllymal derivatives, such as cartilage, bone 
and connective tissue. » 
Anne 1\. l\necht & Marianne Bronner-Fraser Nafure Reviews Genetics 3, 453-461 2002 
Figure 1: Neural crest cells migration and differentiation, from[5} 
NB was first described in 1910 by Dr James Homer Wright [6] and nowadays its frequency is about 
7% of cancers in children younger than 15 years [7], 30% of cancers in newborns [8], in addition to 
accounting for 15% of deaths in pediatric oncology [7]. Therefore, it is the most common and deadly 
extracranial solid tumor found in children, with a median age of 17 months at diagnosis [9]. 
,..: 
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NB develops in different anatomie sites of sympathetic nervous system: about 50% of NB in the 
adrenal medulla with the remaining portion distributed among cervical, thoracic, abdominal or pelvic 
sympathetic ganglia [10]. The heterogeneity of sites can be explained by the migration pattern of 
immature neuroblats during fetal development of sympathetic nervous system. 
Clinical presentations range from local tumors without symptom to severe metastatic disease, 
depending on tumor localization, volume and degree of invasion. Metastatization occurs by lymphatic 
or hematogenous tracts and can involve bone marrow, bone, lymph nodes, liver, intracranial and 
orbital sites, lung and central nervous system [11]. NB of 4S stage ("S" for "special") is an exception 
with metastasis restricted to liver, bone marrow and skin [11]. Tumor and metastasis can compress 
digestive, respiratory, neurologie and urinary systems. Orbital metastasis can manifest with periorbital 
swelling and proptosis ("raccoon eyes") and skin metastasis as blue subcutaneous nodules [12]. 
Catecholamines secretion can induce tachycardia and hypertension [12]. Two major paraneoplasic 
syndromes are associated with NB, which are secretion of vasoactive intestinal peptide (VIP) inducing 
intractable secretory diarrhea, and opsoclonus-myoclonus syndrome (rapid eye movements, ataxia and 
myoclonus) [7]. 
The diagnosis of NB is confirmed by histopathological analysis of tumor tissue or the presence of 
typical NB cells in bone marrow biopsy, combined with elevated catecholamines concentrations in 
urinalysis [7]. Metaiodobenzylguanidine (mIBG) scintigraphy is used to evaluate extent of disease, 
response to treatment and post-therapy evolution [13]. The stage at diagnosis was previously scored 
with the International Neuroblastoma Staging System [14], according to the extent of disease, as 
illustrated in Figure 2 and described in Table 1. 
Stage 
1 
IIA 
IIB 
De finition 
Localized tumor with complete gross excision, with or without microscopie residual disease; 
representative ipsilateral lymph nodes negative for tumor microscopically (nodes attached to and 
removed with the primary tumor may be positive). 
Localized tumor with incomplete gross excision; representative ipsilateral nonadherent lymph 
nodes negative for tumor microscopically. 
Localized tumor with or without complete gross excision, with ipsilateral nonadherent lymph 
nodes positive for tumor. Enlarged contralateral lymph nodes must be negative microscopically. 
III Unresectable unilateral tumor infiltrating across the midline, with or without regional lymph node 
involvement; or localized unilateral tumor with contralateral regional 
lymph node involvement; or midline tumor with bilateral extension by infiltration (unresectable) 
or by lymph node involvement. 
IV Any primary tumor with dissemination to distant lymph nodes, bone, bone marrow, Iiver, skin 
and/or other organs (exceptas defined for stage 4S). 
IVS Localized primaty tumor (as defined for stage 1, 2A or 2B), with dissemination limited to skin, 
li ver, and/or bone marrow (limited to infants < 1 year of age) 
Table 1: International Neuroblastoma Staging System, from [14], previous classification. 
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Figure 2: Illustration of International Neuroblastoma Staging System (INSS), from 
http://www. nant. org/pix/inss.jpg 
The aetiology of NB is unknown, but different chromosomic (diploidy, tetraploidy, lp deletion, l lq 
deletion, l 4q deletion or l 7q gain for example) and molecular alterations (MycN amplification, TrkA, 
TrkB or TrkC anormal expressions for example) have been identified as prognostic factors [10]. The 
most frequent factor of a bad prognostic is MycN amplification, which occurs in 22% of NB cases 
[l O]. Germ line mutations in PHOX2B, and ALK genes account for the majority of familial NB, while 
significant somatic mutation frequencies were found in ALK, PTPNI 1, ATRX, MYCN and NRAS 
[15-17]. 
At diagnosis, risk category-very low, low, intermediate or high-is established with the International 
Neuroblastoma Risk Groupe (INRG) risk classification system, which is the new classification used 
and defines the pretreatment group, according to stage, age, histology, tumor grade, MycN 
amplification, 1 lq aberration and ploidy [18]. 
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INRG Age Histologie Grade of Tumor 11q Pretreatment 
Stage (monthsJ Category Differentiation MYCN Aberration Ploidy Risk Group 
L 1/L2 GN maturing; A Very low 
GNB intermlxed 
L 1 Any, except NA B Ve1y low 
GN maturing or Amp K Hlgh GNB intermixed 
L2 Any, except No D Low 
<18 GN maturing or NA 
GNB intermixed Yes G lntermediate 
No E Low 
Differentiating NA Yes ~18 GNB nodular; H fntermediate 
neuroblastoma Poorly differentiated NA 
or undifferentiated 
Amp N High 
M < 18 NA Hyperdlploid F Low 
< 12 NA Diploid 1 lntermedlate 
12 to < 18 NA Diploid J lntermediate 
< 18 Amp 0 Hlgh 
;:> 18 p Hlgh 
MS No C Ve1ylow 
NA Yes Q Hlgh 
<18 
Amp R High 
Table 2: International Neuroblastoma Risk Groupe (INRG) Consensus Pretreatment Classification 
Shema is the latest neuroblastoma classification, illustration fi·om [18]. 
NB treatment can include surgery, chemotherapy, radiotherapy, biotherapy and observation alone in 
selected situations [7], depending on prognostic factors as shown in Table 2. For tumors with 
favorable biologie features, the aim is to reduce therapeutic intensity to avoid adverse side effects, 
whereas tumors with unfavorable prognostic factors are treated aggressively with chemo-radiotherapy 
[19]. 
Nowadays, 50 to 60% of high risk NBs are resistant to therapy [19] and hope resides in the 
development of new treatments targeting the molecular and genetic abnormalities responsible for the 
development and progression of NB. MycN amplification, which occurred in about 22% of NB cases 
[ 1 O] and is associated with rapidly progressive NB [20], was shown to participate in NB initiation, as 
transgenic mice overexpressing MycN in neuroectodermal ce lis developed NB [21 ]. Despite its 
potential implication in NB initiation, MycN amplification remains a controversial therapeutic target, 
as it is difficult to turn off an amplified gene, as opposed to a mutated gene. Moreover, a Mye inhibitor 
is not easy to design and the risk of adverse side effects is high considering its wide expression pattern 
[22]. In 2012, three targeted therapies seem promising: the radiopharmaceutical 131 1-
metaiodobenzylguanidine (MIBG), immunotherapy with monoclonal antibodies targeting the 002 
ganglioside and inhibitors of anaplastie lymphoma kinase (ALK) [23]. 
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ALKgene 
One of the most studied target genes in the search for new treatments for NB is the Anaplastie 
Lymphoma Kinase (ALK) gene. ALK was discovered in 1994, in a study about the t (2;5) (p23;q35) 
chromosomal translocation being responsible for ALK-NPM protein fusion in a subtype of non-
Hodgkin's lymphoma [24]. Thereafter, ALK was found to be implicated in non-small cell Jung 
cancers, retinoblastomas, melanomas, rhabdomyosarcomas, breast carcinomas, oesophageal squamous 
cell carincomas [25], inflammatory myofibroblastic tumors [26] and finally sporadic and familial NB 
[17]. 
In cancer, ALK activation typically occurs by chromosomal translocation, except in NB cases were it 
is activated by copy number gain, gene amplification or point mutation (Figure 3). Indeed, ALK 
protein is expressed in 92% of NB cases [27], point mutations are present in about 6% to 11 % [28] and 
ALK amplification was found in about 1 % [28]. ALK overexpression, suspected to be associated with 
poor clinical outcome [29], is found in both mutated ALK and wild-type ALK. In NB with wild-type 
ALK gene, negative, low, moderate and high ALK immunoreactivity was shown, although molecular 
mechanisms of overexpression variability have not been understood yet [29]. Even though a clear 
association between ALK mutations and dismal prognostic NB was shown by two independent studies 
[30, 31], it remains controversial [28]. 
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Nonnal slgnaling 
Neuroblastoma 
ALCL / IMT /Lung Ca 
1 r r 1 
RAS PLCy Pl3K/Akt STAT3 
Figure 3: Physiologie and pathologie activation mechanisms of ALK, illustrationji-om [32}. (a) Wild-
type ALK activation by ligand binding. (b) Differentfusion proteins with ALK arefound in some 
cancers, such anaplastie large cell lymphoma (ALCL) , non-small-cell lung cancer (Lung Ca) and 
injlammat01y myofibroblastic tumor (!MT). (c & d) Gene amplification or point mutation occurs in a 
subset of NB and induce ALK activation. Four different molecular signaling pathways have been 
identi.fied with ALK activation: RAS, PLCy, PJJK/Akt and STAT3. 
ALK is located on chromosome 2p23 in humans and on chromosome 17 in mice [33]. 1t is a 
transmembranar protein of 1620 amino acid acting as receptor tyrosine kinase (RTK) [34]. ALK gene 
encodes for a 177 kDa polypeptide. After post-translational modifications, as N-glyocosylation, a 
mature protein of approximately 200-220 kDa is obtained [34]. A part of full-length receptor of 220 
kDa is cleaved in the extracellular domain, which creates a truncated protein of 140 k.Da [35]. 
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Figure 4: Structure of ALK. The most of ALK mutations are in kinase domain. 
COOH 
The heparin-binding growth factors Pleiotrophin (PTN) and midkine (MK) were identified as putative 
ALK ligands [36, 37], but binding between ALK and PTN is controversai because the interaction 
failed to be reproduced [34, 35]. After ligand binding induces receptor dimerization and activation via 
autophosphorylation [35], ALK activates different pathways of intracellular signaling molecules by 
phosphorylation: RAS/MAPK [38], JAK/STAT [39], Pl3K/AKT [40] and PLCy pathway [41]. These 
pathways, which are interconnected, are not ALK specific and can be activated by other RTKs [25]. 
Although the ALK gene was recently extensitvely studied and its expression profile suggests a role in 
nervous system development [42], its function is not yet fully understood. ALK mRNA is expressed in 
human in central and peripheral nervous system regions [24, 43] and ALK is described as having a 
role in neuronal differentiation [38]. In mi ce, its location is similar with expression starting the 11 '" 
day of embryogenesis, and declining after birth to reach low quantities in newborn [42]. In ALK 
knockout mice, an "antidepressant profile" was reported, with an increase in basal hippocampal 
progenitor proliferation and in basal dopaminergic signaling within the frontal cortex [ 44]. 
Interestingly, ALK Înay play a role in tumorigenicity, as it appears to be implicated in the regulation 
of cell survival and in apoptosis [34, 45]: in the absence of ligand, ALK seems to have a pro-apoptotic 
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role, while in presence of ligand or intrinseque activation it becomes anti-apoptotic , thus qualifying 
ALK as a dependent receptor [ 45]. Moreover, PTN ligand was shown to have an anti-apoptotic 
signaling through ALK in NIH3T3 fibroblasts (46]. Finally, MK ligand was described as "growth, 
survival and angiogenic factor during tumorigenesis through ALK" (37]. 
ALK gene mutations 
The point mutations Tl !SIM, Tl 151R, T1087I, Rl 192P, Gl 128A, Rl275Q, Il250T, AI099T and 
R1464STOP have been found in germ lines (17, 30, 31, 35 , 47-49], whereas in somatic lines 
approximately sixteen activating point mutations (FI 174L, FI 174C, FI 174V, Fl 1741, Al234T, 
Fl245L, Fl245C, F1245V, Rl275Q, Rl275L, KI062M, Ml 166R, D1091N, Il 171N, 11250T, 
Yl278S) have been described [17, 28, 30, 31 , 48] . The two most frequent mutations are Fl l 74L and 
RI 275Q corresponding to 34.7% and 49% of mutated ALK, respectively (28] . The ALK-F l l 74L 
mutation is only present in sporadic NB cases, whereas ALK-R 1245Q has been found in sporadic and 
familial NB cases (17, 50]. Both mutations lead to a constitutive activation of ALK protein by 
autophosphorylation [28], although ALK-F l l 74L has an increased transforming capacity compared to 
ALK-Rl 245Q [28]. Most mutations occur in the kinase domain of ALK (Figure 4), with different 
signaling pathways being activated depending on mutation type. For example, in Ba/F3 cells 
transduced with ALK-F 1l74L, the phosphorylated signaling molecules were ST A T3 and AKT, 
whereas ALK-R l 245Q phosphorylated efficiently ERK 1/2 and AKT [ 48]. 
Cooperation between MycN and ALK 
The Mye family consist of transcription factors which regulate the expression of man y genes and has 
"roles in cell growth, proliferation, cytoskeletal structure, cellular adhesion and motility, 
differentiation, and apoptosis" (51]. The overexpression of Mye proto-oncogenes, such as MycN, c-
Myc, and MycL, can induce a deregulation of growth and proliferation [! O]. c-Myc and MycN were 
also shown to maintain and re-establish stem cell functions in mouse [52], and c-Myc or v-Myc is 
often used to immortalize neural crest stem cells [53, 54]. 
MycN is located on chromosome 2p24 [10], near the position of ALK at 2p23 [33]. Despite this close 
positioning, co-amplification of ALK and MycN is rare and observed only in unfavorable cases [55, 
56], although MycN amplification is frequently associated with ALK-F 1l74L mutation. A meta-
analysis showed 58.8% of MycN amplification associated with FI l 74L, against 21 ,6% with wild-type 
ALK or R1275Q mutation, and the prognostic seems to be worse with both gene alterations, than with 
only one [28]. 
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ALK inhibitors 
ALK is a promising therapeutic target, as its expression is not ubiquitous and it is mainly present in 
the neuronal system, which limits adverse side effects (25]. Moreover, immunological response 
against ALK should not induce a relevant autoimmune disease [25]. 
Crizotinib is the first drug to be approved by the US Food and Drug Administration (FDA) for 
treatment of ALK rearranged cancers, such as NSCLC, anaplastie large-cell lymphoma and 
inflammatory myofibroblastic tumor [57]. In NB cases, preclinical testing showed a good response of 
NB cases with ALK amplification or R l 275Q mutation, but a poor response in NB with F 1l74L 
mutation [23] . One explanation is that the point mutations of ALK in its kinase domain affect ALK ' s 
3-dimensional structure, which influences inhibitor binding [50]. 
In preclinical trials, the TAE-684 ALK inhibitor was shown to induce regression of murine NB 
initiated by ALK-F 1l74L in the transgenic NB mouse mode! , and was also effective in inhibiting 
tumor growth ofmurine NB initiated by both ALK-F1174L and MycN [58]. 
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Aims of the project 
Different chromosomic or molecular abnormalities were identified in NB, which are associated with 
low or high risk groups. The ALK receptor tyrosine kinase is expressed in the majority of NB: 
frequently overexpressed or mutated, but rarely amplified. As NB is believed to arise from primitive 
neural crest stem cells, we planned to investigate whether wild-type or mutated ALK in neural crest 
progenitor cells could drive the development of NB, and thereby determine whether ALK plays an 
oncogenic role in NB initiation. 
In 2010, the pediatric oncology research laboratory of CHUV performed preliminary analysis using 
Monc 1 cells [53] , a neural crest progenitor cell (NCPC) li ne immortalized by constitutive v-Myc 
expression. The mutations ALK-F l l 74L and -R l 275Q, provided by Isabelle Janoueix-Larouseix [ 17], 
were introduced in Monel cells by retroviral infection using the pMigrl vector. When injected 
subcutaneously in nude mice, Monc 1-ALK-F l l 74L cells rapidly gave ri se to tumors, followed by 
Monc 1-ALK-R l 245Q cells, white only few mice engrafted with the negative controls Monc 1 cells 
produced tumors with longer tumor intake. 
Monc 1-ALK-F l l 74L and Monc 1 were then injected orthotopically in the adrenal glands of nude mice, 
which resulted in tumor growth in both groups, with faster growth present in the ALK-F l l 74L 
injected mice. Given these results, where negative controls induced tumor growth, an influence of the 
v-Myc oncogene--constitutively present in Monc 1 cells-was suspected to take part in NCPC 
transformation. 
For this study, we used the JoMa 1 cells [54] provided by Professor Lukas Sommer. These cells were 
isolated from the neural crest of ROSA"'Nea_c-myc-ERT transgenic mice and immortalized by an 
inducible c-Myc-ER. In presence ofTamoxifen, c-Myc is activated by the binding ofTamoxifen to the 
ER motif, allowing the translocation of c-Myc-ER into the nucleus, which ensures proliferation and 
maintains cells in an undifferentiated state. ln absence of Tamoxifen, c-Myc is inactivated by its 
retention into the cytoplasm, which allows cell differentiation and avoids the side effects of c-Myc. 
This cell line was shown to express NCSC markers. 
The aim of this study is to evaluate, in vitro and in vivo, the effect of wild-type and mutated ALK on 
JoMa 1 cells to determine the oncogenic role of ALK in NB initiation and progression. 
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Materials and methods 
JoMal cell culture 
JoMal cells were generously given by Lukas Sommer, and were cultivated in dishes coated with 
1 mg/ml fibronectine (Sigma). JoMal medium was composed of Dulbecco's Modified Eagle 
Mediurrvf-12 (Gibco ), supplemented with 1 % N2-Supplement (Gibco ), 2% 827-Supplement (Gibco ), 
0.5 ng/ml EGF (R&D), 0.2 ng/ml FGF (PeproTech), 1% Penicillin-Streptomycin (Gibco), and 10% 
Chicken-Embryo-Extract (CEE, produced according to [59]). For c-MycER activation, 200 nM 4-
0HT (Sigma-Aldrich) was added to JoMal medium. 
Proliferation assay by cell counting 
15'000 JoMal cells were cultivated in 3 plates of 12-well with and without Tamoxifen. At 48, 72, and 
96 hours, one of the remaining cultured plates was selected for cell counting using a counting 
chamber. 
Proliferation assay by OD 
Cells (103 in IOOuL of JoMal medium) were plated in quadruplicates in 96-well plates (Corning !ne) 
coated with ftbronectin (Sigma). Tamoxifen was added every day, diluted in 1 uL of JoMa 1 medium. 
After 0, 48, 72, and 96 hours, cell viability was assessed using the MTS/PMS cell proliferation kit 
(Promega). OO was measured using an ELISA reader (Dynatech MRX Microplate Reade1} 
JoMal cell transduction 
ALK-wt-, ALK-Fl 174L-, and ALK-R1245Q-pcDNA3 constructs were generously provided by 
Isabelle Janoueix-Lerosey and Olivier Delattre. The ALK cDNA Xhol-EcoRI fragments were 
introduced into Xhol-EcoRI sites of the pMigr plasmid. The day before transduction, 2x 106 293T cells 
were plated on 6-well plates in DMEM (Gibco) complemented with 10% FCS (Sigma) and 1 OO U/ml 
Penicillin-Streptomycin (Gibco). 250 µlofa DNA solution containing 10 ~tg ofpMIGR vector, 10 µg 
of pHit60 and 1.25 µg of pCG was mixed with 250 µl CaC!i 0.5M, and incubated at RT for 1 O min. 
The CaCb/DNA mix was added to 500 µl of HBS buffer pH 7 .1 (280 mM NaCl, 10 mM KCI , 1.5 mM 
Na2HP04-2H20, 12 mM Glucose and 50mM HEPES), incubated for 15 min at RT, and then added 
onto 293T cells. Cells were incubated at 37°C for 16 hours, after which the viral medium was replaced 
by fresh culture medium containing 1 OmM sodium butyrate (Sigma). After 8h incubation at 37°C, 
transfection medium was replaced by fresh JoMa 1 medium and cells were incubated again for 20h at 
37°C. Viral supernatant was harvested, supplemented with 1 µl/ml polybrene (Sigma), filtrated 
through a 0.45 µm .. füter (Milian SA) and added to JoMal cells--seeded in a 6-well plate one day 
prior--at a density of 2xl05 cells per well. After 7h incubation of JoMal cells at 37°C, viral 
supernatant was replaced by fresh JoMal medium. 
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Flow Cytometry 
JoMal cells were stained with anti-p75 antibody (Rabbit anti-p75(AB1554, Millipore) and anti-rabbit 
antibody (AF647, LifeTechology)) and analyzed for the expression of p75 marker by FACS (Becton 
Dickinson). Cells were then sorted by FACS Aria 1 according to GFP fluorescence. 
Qualitative RT-PCR 
Total RNA were extracted from cell lines using the RNeasy Mini kit (Qiagen), then quality and 
concentration of each RNA sample was measured by a Nanodrop (Agitent Technologies). RNA (500 
ng) were reverse-transcribed to produce cDNA, using PrimeScript™ RT reagent Kit using random 
primer and oligo dT according to the manufacturer's instructions (TAKARA Bio Inc. Shiga). The 
expression levels of various genes (Table 3) were analysed by PCR using GoTaq Hot Staii Kit 
(Promega). The cycling reactions consisted of2min at 95°C followed by 35 cycles of30s at 95°C, 30s 
at T-annealing (Table 3) and 30s at 72°C, with a final extension step of 5min at 72°C. Then, PCR 
reactions were loaded on 2% agarose gels. UV revelation was visualized with Alphalmager (Alpha 
lnnotech). 
Marker T 0 annealing Primer sequences 
NCSC markers p75 65 For 5 ' -GAA TGC GAG GAG A TC CCT GG-3 ' 
Rev 5' -GGA GCA ATA GAC AGG AAT GAG G-3 ' 
Snail 60 For 5' -CAC CCA TAC AGG TGA GAA GC-3 ' 
Rev 5' -TGT CCT GGA TGA CAG AAC CA-3 ' 
Slug 65 For 5 ' -GGA GAG ACT GCA GCC CAA GC-3 ' 
Rev 5 ' -GTG TGC CAC ACA GCA GCC AG-3 ' 
Soxlü 60 For 5 ' -CCC ACA CTA CAC CGA CCA G-3 ' 
Rev 5 ' -GTC GTA TAT ACT GGC TGC TCC C-3 ' 
NB markers Phox2b 60 For 5 ' -CAC CAG AGC AGT CCG TAC G-3 ' 
Rev 5 ' -TCT GGA ACC ACA CCT GGA C-3 ' 
TH 60 For 5 ' -ATG CTG TTC TCA ACC TGC TC-3 ' 
Rev 5 ' -GAA CCA GGG AAC CTT GTC C-3 ' 
Neuronal markers Nefh 60 For 5 ' -GCA GCC AAA GTG AAC ACA GA-3 
Rev 5 ' -CTG AAT AGC GTC CTG GTA GG-3 ' 
Mashl 60 For 5' -TTG AAC TCT ATG GCG GGT TC-3' 
Rev 5'-GCC ATC CTG CTT CCA AAG TC-3 ' 
Glial marker GFAP 60 For 5' -ATC CCA CGT TTC TCC TTG TC-3 ' 
Rev 5 ' -ATC TTG GAG CTT CTG CCT CA-3 ' 
Smooth muscle markers Calponin 60 For 5 ' -GAA ATA CGA CCA TCA GCG GG-3 ' 
Rev 5 ' -CCA GTT TGG GAT CAT AGA GG-3 ' 
y-actin 60 For 5 ' -GGC TTT GCA GGA GAT GAT GC-3 ' 
Rev 5' -GAG GTA GTC TGT GAG A TC CC-3 ' 
Melanocyte marker Tyr 60 For 5 ' -GTA GCA TGC ACA ATG CCT TAC-3 ' 
Rev 5'-AGA GCG GTA TGA AAG GAA CC-3' 
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Chondrocyte markers Col2a 60 For 5'-TTC TGC AAC ATG GAG ACA GG-3' 
Rev 5 ' -GCT GIT CTT GCA GTG GTA GG-3 ' 
Sox9 60 For 5 ' -TGA ACG CCT TCA TGG TGT GG-3' 
Rev 5 ' -GTT CTT CAC CGA CTT CCT CC-3 
ALK ALK 62 For 5 ' -TGT TGC CTC TCC TCG ATG TG-3 ' 
human Rev 5 '-TGT CTT CTC CGC TAA TGG TG-3' 
ALK 62 For 5 ' -TGC CAG AAG TGT GTT CAG AAC-3' 
mouse Rev 5'-CCC TTC CAT GAA GGC TTC AG-3 ' 
Control G3PDH 60 For 5 ' -GTG AAG GTC GGT GTG AAC G-3 ' 
Rev 5 '-GGT GAA GAC ACC AGT AGA CTC-3 ' 
Table 3: Primers usedfor RT-PCR of transduced JoMal cells and subcutaneous tumors. 
Real-Time PCR 
The expression levels of c-Myc, MycN, and P-actin were assessed by real-time quantitative RT-PCR 
using the Corbett Rotor-Gene 6000 real-time cycler (Qiagen) and the Quanti Fast SYBR Green kit 
(Qiagen). The references of the primers used are reported in Table 4. 
Primer References 
c-Myc QT00096 l 94, QuantiTect, Qiagen 
MycN QT00252 l 96, QuantiTect, Qiagen 
{3 -actin QTO 1136772, QuantiTect, Qiagen 
Table 4: Primers usedfor Real-Time PCR of JoMal cells 
The cycling conditions comprised 5 min polymerase activation at 95°C, followed by 40 cycles of 1 Os 
at 95°C, 20s at 60°C , and ls at 72°C for fluorescence acquisition . A standard curve was performed for 
c-Myc, MycN, and P-actin with serial dilutions of a reference cDNA to ensure that the amplification 
efficiencies were comparable. The expression levels of the c-Myc and MycN in each cell li ne were 
normalized respective to the level of the housekeeping gene p-actin. The ratio of c-Myc and MycN to 
P-actin gene expression was evaluated using the t-.Ct method. 
Immunob/otting analysis 
JoMa l cells were harvested by trypsinization, washed with PBS, resuspended in 2x pellet cells volume 
(PCV) of RIPA buffer and kept at 4°C. This RIPA lysis buffer was composed of lümM NaPi buffer 
(pH 7.8), 60 mM NaCI, 1% Triton XlOO, 0.5% deoxycholic acid, 0.1% SDS, 10% glycerol , 25 mM p-
glycerol phosphate, 50 mM sodium tluoride (NaF), 2 mM sodium pyrophosphate (NaPPi), 1 mM 
sodium orthovanad~Je (Na3V04) and lx CompleteTM protease inhibitor (Roche). The lysates were then 
incubated on ice during 15 min with some vortexing and centrifugated for 15 min at 4°C at 14'000 
rpm. Supernatants were removed and protein concentrations were measured with the BCA kit. 
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Protein extracts of 45-50µg were loaded on 7.5% or 10% SOS-PAGE and transferred on nitrocellulose 
membranes. Blots were blocked with 5% milk diluted in TBS-Tween20 0.1 % and incubated overnight 
at 4°C with rabbit polyclonal antibodies specific for c-Myc (Santa Cruz Biotechnology lnc.), and ALK 
(lnvitrogen) or mouse monoclonal antibody for ~-actin antibody (Sigma). Binding of the first antibody 
was revealed by incubation with either goat anti-rabbit lgG-HRP or goat anti-mouse IgG-HRP 
(Jackson ImmunoResearch). Bound antibodies were revealed using the ECL Advanced system (GE 
Healthcare) or Lumi-light Western Blotting Substrate (Roche). 
Pltosplto-immunoblotting 
To obtain the protein extracts, JoMa 1 cells were first resuspended in lysis buffer containing 10 mM 
Tris-Hel (pH 7.4), 150 mM NaCI, 5 mM EDTA, 25 mM ~-glycerophosphate, 10% glycerol, 1% NP40, 
0.25 % Na deoxycholate, 20 mM NaF, 1 mM Na pyrophosphate, 1 mM Na3 V04 and 1 x protease 
inhibitor. Then, cell lysates were sonicated three times for !Os, and centrifugated at 13'000 rpm at 4°C 
during 30min. The supernatants were recovered and protein concentrations were determined with 
BioRad Protein Assay and aliquoted for storage at 80°C. 
Protein extracts (100 ug) were separated on SOS-PAGE gels, and then transferred to Immobilion-P 
PVDF membranes (Millipore). Membranes were blocked for 1 h in TBS-Tween 0.1 % containing 2% 
ECL AdvanceTM Blocking Agent (GE Healthcare) at RT and incubated overnight at 4°C with the 
phospho-ALK (AssayBioTech), phospho-AKT (Cell Signaling), phospho-STAT3 (Cell Signaling) or 
phospho-ERK (Cell Signaling) polyclonal rabbit antibodies. Then, membranes were incubated with 
peroxidase Goat Anti-rabbit (Jackson ImmunoResearch) and revealed using the ECL Advanced 
system (GE Healthcare). Membranes were stripped 10 min at 50°C in 2% SOS, 65.5 mM Tris-HCL 
pH 6.8 and 1 OO mM ~-mercaptoethanol, and finally total protein expressions were detected as loading 
contrai by the same process (ALK (lnvitrogen), AKT (Cell Signaling), STAT3 (Cell Signaling), ERK 
(Cell Signaling)). 
Spltere culture assay 
JoMal sphere culture was performed in a neural crest stem cell medium (NCSCm), adapted from (60] 
and containing DMEM-Fl2 (Gibco) complemented with 20 ng/ml FGF-2 (Peprotech) , 20 ng/ml IGF-1 
(Peprotech), 1 % N2-supplement (Gibco), 2% 827-supplement (Gibco), 1 % Penicillin/Streptomycin 
(Gibco ), 50 µM 2-mercaptoethanol (Merk), 35 ng/ml retinoic ac id (Sigma) and 15% CEE. 
104 cells in 1 ml of NCSCm were cultured in PolyHema (poly (2-hydroxyethyl methacrylate), 16 
mg/ml in EtOH, Sigma) coated 12-well culture plates, to prevent cell adhesion. Cells were passed 
every 7 days by dissociation with 0.05% trypsin-EDTA (Jnvitrogen) for 3.5 min and stopped with 
1 mg/ml Trypsin-Inhibitor (Sigma). After centrifugation, ce Ils were resuspended in NCSCm, counted, 
and 104 cells were plated for secondary sphere culture. 
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Metltylcel/u/ose 30 growth assay 
JoMal cells were grown in a medium composed of 53% methylcellulose (Fluka, and prepared as per 
(61 ]), 17% FCS (Sigma) and 30% Dulbecco's Modified Eagle Medium (Gibco). Tamoxifen was added 
every two days in 100µ1 DMEM with 10% FCS and Penicilin-Streptomycin. After 2 weeks, cell 
colonies were counted using an optic microscope and colored with a mix of 50% MTS/PMS 
(Promega) and 50% DMEM (Gibco) during 2 hours. 
Differentiation assay 
105 JoMa 1 cells were plated per 6-well dish coated with 1 mg/ml Poly-D-Lysin (Millipore) and 
1 mg/ml Fibronectin (Sigma), in JoMa 1 medium without 4-0HT. After 24 hours, 50 ng/ml BMP2 
(R&D) was added for neuronal differentiation, 34 ng/ml GGF2 (Reprokine) for glial differentiation, or 
1 ng/ml TGFb (R&D) for smooth muscle differentiation. These mediums were changed every day and 
after 6 days, potentially differentiated JoMa 1 cells were frozen to execute a RT-PCR analysis with 
specific markers: Nefh and Mash 1 for neurons, GF AP for glia, calponin and y-actin for smooth muscle 
(Table 3). 
For chondrocytes differentiation, JoMa 1 cells were plated in 6-well dishes coated with fibronectine. 
The medium was DMEM (Gibco) supplemented with 10% FCS (Sigma), 100 U/ml Penicillin-
Streptomycin (Gibco), 0.05 mg/ml Ascorbic acid (Sigma), 2 ng/ml TGF~ (R&D) and 0.1 µg/ml 
Dexamethasone (Sigma), and was changed every third day. RT-PCR analysis was done after 21 days 
with Col2a and Sox9 markers (Table 3). 
In vivo studies 
Ali animal experiments were carried out with athymie Swiss nude mice (BALB/C nu/nu) in 
accordance to the European Community guidelines (directive no. 86/609/CEE). For injections, mice 
were anaesthetized using Jsoflurane (Baxter) by inhalation. 
In heterotopic assays, groups of 3 mice were subcutaneously injected with a 25 G needle connected to 
a 1 ml syringe in both flanks with 5x 105 transduced JoMa 1 cells in 200 ut Dulbecco modified Eagle 
medium (DMEM)/Fl2 (Gibco) and BD MatrigelTM Basement Membrane Matrix (BD Biosciences) in 
a 1: 1 propo1tion. 
01thotopic injections were performed as previously described [62]. After a midline incision, 1.5x t 05 
cells in 10 µL PBS were injected in the left adrenal gland under microscope using a 28 G needle 
connected to a Hamilton syringe. The abdominal incision was closed with skin clips. 
Tumor take and growth were followed up using calipers twice a week for subcutaneous injections and 
by ultrasound every 3, 7, or 14 days according to progression for mthotopic injections. Subcutaneous 
tumor volumes were ca lculated using the (lengthxwidth 2)/2 fo rmula and 01thotopic tumor vo lumes 
.. 
using fo rmula 4 x n / 3 x (depth x sagittal x transversa l) / 6. 
Mi ce with tumor volumes greater than 1000 mm3 were sacrifi ced. 
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A sample of every subcutaneous tumor was embedded in paraffin and the residual was snap-frozen 
into liquid nitrogen, for later protein or RNA extraction using RNeasy Mini kit (Qiagen). 
Orthotopic tumors were split into four pieces: one for paraffin-embedded tissue formation, one for 
RNA extraction, one for protein extraction, and one for cell dissociation. Moreover, bone marrow was 
extracted for further analyses by flow of PBS into femoral bones using 25G needle connected to a 1 ml 
seringue. 
Immu nohistochemistry 
Ail immuno-labelling were performed by Lausanne Mouse Pathology Facility. First, standard 
hematoxylin and eosin (H&E) staining was performed on ail subcutaneous tumors. Secondly, three 
tumors per group were chosen for immunohistochemistry (IHC) with different markers (Table 5) to 
identify the type oftumor generated. 
Antibody 
Antigen host Cell type recognized Source 
na me 
CD44 Rat Mesenchymal lineage, NB 550538, BD Pharmingen 
NSE Rabbit Neuronal lineage, NB, melanoma 22521, lmmunoStar 
NF Mo use Neuronal lineage M0762, DakoCytomation 
SlOO Rabbit Neural crest lineage Z031 l, Dako 
Pax3 Mo use Melanocyte lineage 
Given by Bhushan Sarode, 
EPFL 
Tyr Rab bit Melanocyte lineage 
Given by Bhushan Sarode, 
EPFL 
CD99 Rabbit Ewing sarcoma Orb 13719, Biorbyt 
NCAMI 
Rabbit NB 14255-1-AP, Proteintech 
=CD56 
TH 
Mo use 
Dopaminergic and noradrenergic 
MAB3 l 8, Millipore 
neurons, NB 
Synaptophysin rabbit 
Neurosecretory vesicles, 
Ab23754, abcam 
including presynaptic vesicles 
ALK 
rab bit lnvitrogen (Tyr1604) 
Table 5: Antibodies usedfor !HC of subcutaneous tumors 
Statistical analysis 
Statistical significance of the results was analysed using t-test, one-way ANOVA or two-way A NOVA 
analysis using GraphPad Prism 5.04 software (GraphPad Software, lnc.). 
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Results 
Switch of c-MycER 
Western-Blot of c-MycER 
JoMal cells express a c-MycER, which is activated by Tamoxifen. The active form of c-MycER 
translocates into the nucleus to regulate genes expression, whereas the inactive form stays in 
cytoplasm. To check the switch of c-MycER from the active to the inactive configuration, nuclear and 
cytoplasmic proteins were extracted from JoMal cells treated with and without Tamoxifen and c-
MycER localization was analyzed by Western-Blot (Figure 5). 
cytoplasmic nuclear 
-Tamox + Tamox - Tamox + Tamox 
c-MycER (105 kD) 
c-Myc (67 kD) 
(3-actin (42 kD) 
Figure 5: Western-Blot of c-MycER. "- Tamox " = JoMa l cells cultured without Tamoxifen during 5 
days, "+ Tamox " = cells cultured with Tamoxifen. fJ-actin was used as loading contrai. 
In the presence ofTamoxifen, the c-MycER protein was observed in the nucleus and in the cytoplasm; 
whereas in the absence of Tamoxifen, c-MycER protein decreased in the nucleus. This means that the 
inactive form is not transported into the nucleus and thus remains inactive. Endogenous c-Myc 
expression was a little higher in the nucleus in presence of Tamoxifen, suggesting a weak effect of c-
MycER activation on endogenous c-Myc expression. 
Growth assay 
A proliferation assay was performed to highlight the effect of c-MycER activation on cell 
proliferation, which should be increased in presence of Tamoxifen. As illustrated in Figure 6, JoMa 1 
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cells cultured with Tamoxifen grew faster than those without Tamoxifen. The difference became 
visible after about 48 hours, and at 96 · hours there were four times more cells in presence of 
Tamoxifen. This also shows that c-MycER inactivation by Tamoxifen withdrawal impaired JoMal 
cell proliferation, as expected. 
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c 
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hours 
Figure 6: Proliferation assay by cell counting. "No Tamox" = cells cultured in absence of Tamoxifen 
ji-om lime 0, "Tamox " = cells cultured with Tamoxifen. 
Transduction of JoMal cel/s 
Cel! sorting oftransduced cells 
ALK-wt, ALK-FI 174L, and ALK-Rl245Q were stably overexpressed in JoMal cells by retroviral 
infection using the pMigrl vector, which encodes for the Green Fluorescent Protein (GFP). 
Transduction efficiency was analyzed by measuring the percentage of the GFP positive cells by 
F ACS. In addition, the expression of the NCSC marker p75 was measured to ensure that transduced 
cells remained undifferentiated. The FACS analyses (Figure 7) showed that most cells were p75 
positive and that between 91 % and 58% of cell populations were transduced . P75+ cell sorting was 
therefore not necessary, but the GFP positive JoMa 1 cells were s01ted by F ACS, to get pure 
populations of transduced cells. After cell sorting, another F ACS for GFP expression showed that cell 
populations were enhanced in transduced cells with new percentages between 90.7% and 97.2%. Thus, 
almost pure populations oftransduced JoMa 1 cells expressing the p75 NCPC marker were obtained. 
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Figure 7: (A.) p 75 expression in transduced JoMal cells. (B.) GFP expression in transduced cells 
before cell sorting. (C.) GFP expression in transduced cells after cell sorting. 
~: 
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ALK expression in transduced cells 
The next step was verifying the ALK mRNA and protein expression by RT-PCR and Western-blot, 
respectively. As shown by RT-PCR (Figure 8A), ALK mRNA was present in ALK-wt, ALK-Fl 174L, 
and ALK-R 1245Q JoMal cell lines. ALK protein was also produced by these ce!! populations, as 
observed by Western-Blot (Figure 8B). The presence or absence of Tamoxifen did not affect ALK 
mRNA and protein expressions. But interestingly, ALK-wt seemed to be expressed as strongly as 
mutated ALK. Thus, transduced cells stably express wild-type and mutated ALK proteins. 
A. RT-PCR 
wi th Tam oxifen w ithou t Tamoxifen 
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B. Western-Blot 
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Figure 8: (A.) Detection by RT-PCR of ALK mRNA in transduced cells cultured with and without 
Tamoxifenfor 72 hours. GAPDH ·was used as internai contrai. (B.) Detection by Western-Blot of ALK 
prote in in transduced cel/s cultured with and without Tamoxifenfor 96 hours. [J-actin was used as 
loading contrai. 
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Characteristics oftransduced JoMal cells 
RT-PCR 
We analyzed the phenotype of the transduced JoMal cells by RT-PCR. Different markers were used to 
ensure NCPC phenotype, such as the early neural crest marker p75, and the genes associated with 
neural crest induction Sox 10, Slug, and Snail [63-65]. We also used different markers for cells types 
which can be derived from NCPC, such melanocyte, chondrocyte, neuron, smooth muscle, glia and 
NB to test their state of differentiation. 
A . B. 
+Tamoxife n +Tamoxifen -Tamoxifen 
,--1--i 
';: u. 
"' 
';: u. 
"' .~ :5 ~ ~ :5 :5 :5 2 <( <( <( <( <( <( ;;: .... ;;: .... .... ;;: .... .... .... .... .... i .. .. 0 "' .. "' i ~ 0 2 2 2 2 2 N 2 ~ ~ N ~ ~ ~ ~ ~ ~ X ~ ~ ~ ~ ~ X 
f NBmarkers Phox2b p75 Slug 
Glial marker { GFAP 
NCSC 
marke rs 
Snal l 
{""'"'"' Smooth muscl e marke rs r-actin 5:ox l 0 M elanooyte f v• marker 
{'"" Chondrocyte marke rs 0>9 
Control {GA PDH 
r· Neuronal marke rs rv1ashl 
Control { GA PDH ------
•••••• 
Figure 9: Expression levels of various NCSC and differentiation markers analyzed by RT-PCR in total 
RNA.from JoMal parental and transduced cells treated with Tamoxifen (A) or without Tamoxifen (B). 
As shown in Figure 9, the NCPC markers expression was variable in each cell line, except Slug in 
JoMal-ALK-wt cells which was not expressed. Melanocyte, neuron, glia, and NB markers were not 
detectably expressed. Smooth muscle and chondrocyte rnarkers were found in transduced JoMa 1 cells, 
but also in the parental JoMal cell line, which rneans that JoMal cells already presented these 
differentiation rnarkers. 
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Differentiation test 
As JoMal cells are NCPC, they should display some pluripotential abilities. Parental JoMal cells were 
tested first to verify differentiation capacity of the parental cell line. To assay for this prope1ty, BMP2 
was added to the JoMal medium during six days to induce neuronal differentiation, GGF2 was added 
for glial differentiation, TGF~ for smooth muscle induction, and a special medium for chondrocyte 
transformation. Morphology changes were photographed with an optical microscope (Figure 16) and 
differentiation markers were assayed by RT-PCR (Figure 17). 
Jùma~ GGF2 
Figure 16: Dijferentiation assay. Pictures of dijferentiated JoMa 1 cells ta ken after 6 days of induction 
with BMP2, GGF2, TGF/J, and in absence ofTamoxifen as control. 
The most important morphologie change occured after TGF~ induction, where cells became long and 
slender (Figure 16). The chondrocyte medium induced non adherent, floating, round and small cells 
(not shown). 
After 6 days of differentiation induction, NCSC marker expression was expected to decrease while 
differentiation markers should appear in their respective differentiation pathways. As illustrated in 
Figure 17, a weak decrease in NCSC markers occurred for p75 with TGF~ induction, for Snail with 
BMP2 and TGF~ induction, and in Soxl 0 with BMP2 induction. The glial marker GFAP was not 
detectable. For neuronal markers , Mash 1 was only expressed in JoMa 1 cells without induction and 
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Nefh appeared as much in the absence of Tamoxifen as with BMP2 and GGF2 induction. Smooth 
muscle markers (Calponin 1 and y-actin) were already present in parental JoMa 1 ce lis and no increase 
could be detected by RT-PCR. For chondrocyte induction, no sufficient RNA could be obtained for 
RT-PCR analyses. Therefore, RT-PCR results did not highlight a significant increase in any 
differenciation markers to confirm differentiation in one pathway. 
Vl Vl Vl > > Vl ro ro > > 
-0 
-0 ro ro 
<D <D -0 -0 
X X <D <D 
0 0 N N 
-" E E o.. u.. u.. ~ l9 ~ ~ cD l9 ~ 
+ 1 + + + 
ro ro ro ro ro 
0 E E E E E N 0 Q 0 Q Q :r: ~ ~ 
p75 - ._._ --
NCSC markers Slug 
Snai l 
SoxlO 
Glial marker { GF-AP 
{ 
Nefh 
Neuronal 
markers Mashl 
S h 1 
{
C1l pon inl 
moot musc e 
markers l ' y-ac Ill 
Control { GADPH 
---·--
Figure 17: Expression levels ofvarious NCSC and diflerentiation markers analyzed by RT-PCR in 
total RNAfrom parental JoMal cells treated with or without Tamoxifen or inducedfor diflerentiation 
by BMP2, GGF2, TGFb for 6 days . 
Endogenous expression of c-Myc and MycN 
To see whether there was an influence of c-MycER system on endogenous c-Myc expression, and 
whether the MycN expression level was influenced by c-MycER expression or ALK mutations, 
endogenous MycN and c-Myc mRNA expression levels were measured by Real-Time PCR, as shown 
in Figure 1 O. 
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A. MYC RNA e xpression in transduced JoMal ce lis 
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Figure 10: Expression level of endogeneous c-Myc and MycN mRNA mesured by Real-Time PCR 
(A.) The bar graph represents the ratio between [c-Myc or MycN] and fJ-actin expression. (B.) The 
relative expression of c-Myc and MycN according ta JoMa 1 without Tamoxifen are plotted. JoMa 1 
and transduced cells were culturedfor 4 days in absence (-)or in presence (+) ofTamoxifen (Tamox) 
before RNA extraction. 
We used a mouse primer to detect endogenous c-Myc, so human c-MycER should not be detected. 
Our results show that c-Myc was about 2.5 times more expressed in non-tranduced JoMa 1 cells treated 
with Tamoxifen than without Tamoxifen. c-Myc expression also increased in presence of ALK-
F 1174L and ALK-R1245Q mutants from 3.5 to 4.5 times, respectively , and compared to non-
transduced JoMa 1. Here, an influence of c-MycER was excluded because these groups were cultured 
without Tamoxifen, soit could be attributed to ALK mutations. 
The ratio of MycN/~-actin was weaker compared to c-Myc/~-actin ratio, and didn ' t exceed 0.015 . 
MycN expression seemed to be inversely correlated with c-Myc expression and thus MycN expression 
was reduced when c-Myc was highly expressed in parental JoMal cells with Tamoxifen and in ALK-
R1245Q JoMal cells, but not in ALK-Fl l 74L JoMal cells. 
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Activation of ALK signaling pathways 
Previous study has shown that ALK-Fl 174L and ALK-R1245Q were constitutively activated by 
phosphorylation [28]. To analyze the three major signaling pathways activated by ALK in JoMal 
cells, we measured the phosphorylation of Stat3 , AKT and ERK by Western-Blot in protein lysates 
from transduced and parental JoMa 1 ce lis with and without Tamoxifen (Figure 11 ) . 
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Figure 11: Phospho-Western-Blot of pALK, pStat3, pAKT, and pERK in parental and transduced 
JoMal cells. Total ALK, Stat3, AKT, and ERKproteins were used as loading contrais. 
Both isoforms (140 and 220 kD) of ALK protein were present in the ALK-wt, ALK-Fl 174L, and 
~: 
ALK-R1245Q cell lines. Phosphorylated ALK protein was detected in ALK-Fl 174L, ALK-Rl245Q, 
and weakly in ALK-wt cells, for the 140kD isoform both in presence and absence ofTamoxifen. The 
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220kD isoform was only weakly phosphorylated in ALK-FI 174L and ALK-Rl245Q JoMal cells with 
Tamoxifen. AKT seemed to be more phosphorylated in ALK-FI 174L and ALK-RI245Q cell lines 
with Tamoxifen and in ALK-F 1I74L without Tamoxifen. Phospho-ERK was only enhanced in ALK-
F l l 74L without Tamoxifen. White Stat3 was already highly phophorylated in parental and JoMal-
Migr control cells, no increase in phophorylation could be observed in ALK expressing cells. Thus, 
constitutively activated ALK-F 1174L activates the AKT and ERK pathways in JoMal cells, while 
ALK-Rl245Q shows a preferential activation of AKT pathways, but only in presence ofTamoxifen. 
This also indicates that human ALK-FI 174L and ALK-Rl245Q mutants are functional and able to 
activate downstream signaling pathway in murine cells. 
In vitro assays witlt transduced JoMal cel/s 
Growth assays 
Proliferation assays oftransduced JoMal cells with and without Tamoxifen were performed to analyze 
whether the presence of ALK or one of these mutations affect cell proliferation. The four executed 
tests were not really comparable because the values were inexplicably very different between tests, 
which explains why the error bars are so wide in the means graph (Figure 12 A. and B.). That said, this 
graph shows the main facts observed in each test: cell lines with Tamoxifen grew faster than without 
Tamoxifen, and ALK-F 1174L grew much faster than others groups, followed by Migr, parental 
JoMal , ALK-wt, and ALK-Rl245Q. 
The same test was performed with 25% of JoMa 1 medium to test the resistance of ce lis to stress 
conditions, with reduced amounts of growth factors. As shown in Figure 12 (C. and D.), the 
proliferation pattern of JoMal groups with 25% JoMal medium was the same as with 100% JoMal 
medium. Surprisingly, the proliferation was higher in 25% JoMal medium, which indicates a 
generally increased growth capacity of JoMa 1 cells in such stress conditions, as measured within 96 
hours. 
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Figure 12: Mean of Jour transduced JoMal cells proliferation assays in 100% JoMal medium with 
(A.) and without {B.) Tamoxifen. Mean of two transduced JoMal cells proliferation assays in 25% 
JoMa 1 medium, with (C.) and without (D.) Tamoxifen. 
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Sphere assays 
The self-renewal and proliferation capacities of JoMal transduced cells in non adherent conditions 
were tested by performing sphere assays. 
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Figure 13: The graph represents the sphere-forming capacity of JoMa1 and transduced cells cultured 
in presence or absence ofTamoxifenfor up tofive sphere passages(! ta V). Mean oftwo sphere 
assays, excepl for passage V, where on/y one value per cell line was available. Ta obtain sphere-
forming capacity, the nwnber of cells counted ajier one week in culture was divided by the number of 
plated cells. 
ln absence of Tamoxifen, cells were unable to be maintained over passage Il or 111, except for ALK-
F 1174L- and ALK-R l 245Q-expressing cells. ln presence of Tamoxifen, ail cell lines displayed sphere 
forming capacities over five passages. ln each sphere passage, ALK-F l 174L had the highest sphere 
forming capacity, but the difference between each cell line was the greatest at the v 1" passage with 
ALK-F 1l74L as the highest, followed by ALK-R l 245Q, Migr, ALK-wt, and not-transduced JoMa 1. 
lnterestingly, ALK-F l l 74L and ALK-R l 245Q JoMa 1 cells showed an enhanced capacity to 
proliferate in sphere assays, as their sphere forming capacities increased along with sphere passages 
(Figure 13). 
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Methylcellulose 30 growth assay 
To assay the tumorigenic capacity of transduced JoMa 1 cells in vitro, culture in a semi-sol id medium 
(methylcellulose) was performed. This test allows a prediction of future in vivo assays. 
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Figure 15: (A.) Mean of three methylcellulose assays. (B.) Pictures ta ken with Alphalmager® of one 
representative methylcellulose test colored by MTSIPMS reagent. 
As shown in Figure 15, methylcellulose assays showed that while JoMal parental, Migr, and ALK-wt 
cells displayed similar clonogenic capacity, significantly more colony formation was observed with 
Tamoxifen in ALK-Fl l 74L- and ALK-R 1245Q-expressing cells than in Migr control cells. Moreover, 
colony size was larger in ALK-F l l 74L and ALK-R l 245Q groups, macroscopically detectable after 
staining by MTS/PMS reagent. ln the absence of Tamoxifen, ail cells were only able to form few 
microscopie colonies. ln conclusion, ALK-F l l 74L and ALK-R l 245Q cell lines displayed the higher 
oncogenic capacities in vitro and so were expected to be tumorigenic in vivo. 
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In vivo assays with transduced JoMal cells: subcutaneous and orthotopic injections 
Subcutaneous implantations 
To analyze the tumorigenic effect of ALK-wt and mutants in vivo, transduced JoMa 1 cells were first 
subcutaneously implanted in nude mice. Subcutaneous implantations are generally more permissive, 
Jess invasive, and cheaper than orthotopic implantations, so subcutaneous injections were performed to 
screen in vivo cell growth in nude mice. To analyze the oncogenic role of ALK independtly of c-
MycER activity, no Tamoxifen was given to the mice. As negative controls, we used parental JoMal 
cells and JoMa 1 cells transduced only with pMigr vector, in order to rule out a potential effect of the 
vector. 
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Figure 18: Tumor growth in heterotopic mode!. Mice were sacrificed once tumor volume reached 
1000mm3. Mean tumor volume by groups are plotted ji·om first measures made 7 days post-injection, 
until the first mi ce of the group had to be sacrificed. The basal volume of 40-12 5111111 3 was caused by 
Matrigel7M, a gelatinous mixture in which cells were injected subcutaneously to avoid cell 
dissemination. The remaining contrai mice were sacrificed 60 days post-injection. 
As shown in Figure 18, ALK-F l l 74L-derived tumors displayed a highly rapid growth, as tumors 
reached a mean volume of 450 mm3 in 28 days. ALK-Rl245Q- and ALK-wt-derived tumors 
developed slightly less rapidly and reached 450 mm3 after 43 and 55 days, respectively. ln ALK-
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FI 174L and ALK-Rl245Q groups, 616 (100%) mice developed tumors, while 4/6 (67%) did soin the 
ALK-wt group. Interestingly, the control groups implanted with JoMal and JoMal-Migr cells did not 
induce tumor formation, indicating that tumor growth resulted from ALK expression. 
RNA was extracted from three tumors per group to attempt to characterize tumor type by RT-PCR, as 
shown in Figure 19. The results of the three groups were compared. NCSC markers were expressed in 
ail groups. The p75 marker seemed to be weaker and Snail stronger in ALK-FI l 74L group than in 
other groups. SoxlO signal was higher in ALK-FI 174L and ALK-Rl245Q groups. The differentiation 
markers did not bring out a clear NB profile. Neuronal markers appeared more or less strongly in most 
tumors (Nefh in 6/9 tumors and Mash 1 in 8/9 tumors). Suprisingly the melanocyte marker (Tyr) was 
expressed in one ALK-R l 245Q tumor. For NB markers, only one ALK-wt tumor expressed Phox2b. 
GF AP, a glial marker, was not detected in any tumor. Smooth muscle markers (Calponin 1 and y-actin) 
were more strongly expressed in about three ALK-wt tumors and two ALK-R1245Q tumors. Col2al 
and Sox9, which are expressed in chondrocytes, were strongly expressed in ail tumors . ALK human 
was expressed in ail tumors with the same signal. Thus, it was not possible to confirm the NB 
phenotype of these tumors. 
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Figure 19: RT-PCR analysis of NCSC and differentiation markers in subcutaneous tumors. Three 
representative subcutaneous tumors for each transduced cell population (ALK-wt, ALK-F and ALK-R) 
were analyzed. 
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Subcutaneous tumors were also analyzed by histo-pathology. First, H&E labelling was performed to 
observe the tumor anatomy, cell morphology and whether NB-specific structures were noticed 
(Homer-Wright rosette) . Then, IHC labbeling was performed with different markers to identify the 
tumor type more precisely and exclude the several NB-like tumors, such as Ewing' s sarcoma and 
melanoma. In H&E labeling (Figure 20), the tumors appeared as round or spindle-shaped blue cells. 
According to Dr Pu Yan (Institut Universitaire de Pathologie in Lausanne), ail tumors of ALK-wt, 
ALK-Fl l 74L, and ALK-R1245Q look like NB, with the same cell type and undifferentiated 
rnorphology, but should be correlated with IHC, and melanoma should be excluded. Histologically, no 
Homer-Wright rosettes were found, which are known to be pathognornonic for NB tumor. 
Mark ers 
ALK NCAM CD44 NF CD99 Tyr Pax3 
Tu mors 
Synapse, neura l Ewine 's Mesenchyma l cells, 
crest cell s favorable NB 
Neurons sa rcoma, T-cell Mela nocytes Mela nocytes 
lymphoma 
+++ - +++ 
- -
ALK-wt + + +++ - - -
++ ++ +++ - - -
+ ++ +++ - - -
ALK-F + + +++ - -
-
+ 
- +++ - - -
+ + +++ - - -
ALK-R 
++ +++ +/-+ - -
+ + +++ 
- - -
- = slightly positi ve,~ - = posi tive, - -"-= very posi ti ve, - = nega tive, ... ; . = ml x of posi ti ve and nega ti ve zones 
Table 6: Summwy of H&E and IHC analyses in subcutaneous tumors. Three representative 
subcutaneous tumorsfor each transduced cell population (ALK-wt, ALK-F and ALK-R) were 
analyzed. 
-
-
-
-
-
-
-
-
-
As surnrnarized in Table 6 and illustrated in Figure 20, ALK and CD44 were found in ail tumors. As 
turnors were driven by NCPC transduced with mutated or wild-type ALK, ALK staining was 
expected. CD44 indicated mesenchyrnal cells or favorable NB in human. NCAM was present in most 
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tumors which was compatible with their neural crest origin. The absence of CD99, Tyr and Pax3 ruled 
out Ewing' s sarcoma and rnelanoma, which resemble NB tumors. 
CD99 
Figure 20: H&E and JHC stainings of representative subcutaneous tumors. (A.) H&E of one 
representative tumor of ALK-wt (1.), ALK-Fl 174L (2.), and ALK-Rl 245Q (3.) tumor groups. (B.) 
~· 
Positive markersfound in subcutaneous tumors. (C.) Negative markers found in subcutaneous tumors 
with their positive conh·ols. 
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Orthotopic implantations 
Given the complexity of the interactions between tumor cells and their microenvironment, it was 
crucial to analyze the tumorigenicity of JoMa 1 transduced cells in the orthotopic NB mode!, as the 
orthotopic mode! faithfully reproduces the tumor microenvironment. For negative controls, parental 
JoMa 1 cells and JoMa 1-Migr ce Ils were used, as for subcutaneous injections. Tumor size was 
measured by ultrasonography during tumor growth, in absence ofTamoxifen. 
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Figure 21: (A.) Growth of LAG tumor. The abdominal tumors are not represented. 
(B.) Kaplan-Meier survival curves 
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As shown in Figure 21, ALK-F1174L derived tumors grew the fastest with 516 affected mice. The 
ALK-F1174L mice had to be sacrificed between 24 and 35 days post-injection, except one which did 
not develop a tumor. Ail ALK-Rl245Q mice were sacrificed between 45 and 59 days post-injection. 
Finally, ALK-wt-derived tumors grew the slowest with 5/7 mice affected, which were sacrificed from 
52 to 84 days post-injection. Ali remaining mice were sacrificed 92 days post-injection. At dissection, 
one ALK-wt mouse presented a growing abdominal tumor, while no tumor was found in the last ALK-
wt and ALK-F mice, and none in the negative controls. 
Tumoral invasion in sacrificed mice is illustrated in Table 7. In ALK-Fl 174L group, out of 5 
sacrificed mice, ail presented adrenal tumors, one was associated with a big abdominal tumor, another 
had a small abdominal tumor and the three other mice had a probable metastasis on their spleen (not 
yet analyzed). In group ALK-Rl 245Q, out of 7 sacrificed mi ce, 6 mice presented an adrenal tumor of 
which 5 were associated with an abdominal tumor. The mouse with only an adrenal tumor <lied 
spontaneously without having its metastases analyzed. One ALK-Rl245Q mouse had two immense 
abdominal tumors but no tumor in the adrenal gland. Ali abdominal tumors found in this group were 
just below the peritoneum and sometimes completely stuck to it. In the ALK-wt group, out of 6 
sacrificed mice, 4 presented adrenal tumors and 2 only an abdominal tumor. With respect to 
dissemination, one mouse presented an enlarged, oedemateous, and potentially tumoral kidney (not yet 
analyzed) and another mouse had a possible metastasis on the spleen and an infiltrated kidney. 
G1·01111 l\llouse Day of san1firt Atlnnal filfiltntl kitlney Abtlominal Olhtl'S 
aftt1· orthoto11ic hunor huno1· probable 
iln11I11Utatio11s meta~ta~is (not 
ytt 1malyztcl) 
ALK-F 3-RL l -t 1 1 
4 -RL 29 1 Spleen 
3 -RR 29 1 - Spleen 
3-R 35 1 Spleen 
3-0 35 1 1 1 
ALK-R 6 -RL -t 5 1 1 
6 -R 4 9 1 1 1 Spleen 
6 -LL 5ï 1 1 1 
6 -L 57 l l -
4-RR 56 l - -
6 -0 59 - l Spleen , Sto111ad1 
6 -RR 59 l 1 -
ALK-wt 2 -RL 51 1 
l-R 5 7 l l Spleen 
-t-R 57 l Oeclemateous 
left kiclney 
l -0 n 1 
l -L 84 l -
4-LL 92 1 
Table 7: Day of sacrifice and description of tumoral invasion in orthotopically injected mice 
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Discussion 
NB is known to originate from NCPC, and ALK was found to be mutated or amplified in a subset of 
NB. To analyze the role of ALK in the oncogenesis of NB, we introduced wild-type ALK and its most 
frequent mutations, FI 174L and Rl245Q, in the NCPC JoMal immo1talized with an inducible c-
MycER. First, some in vitro tests were performed to assay the c-MycER system of JoMal cells, the 
stability of transduced cells, their phenotypes, growth and transforming capacities. Then, we injected 
these cells subcutaneously in nude mice, and finally mthotopically in the adrenal gland to determine 
whether ALK wild-type or mutated genes were sufficient to drive neuroblastomagenesis from NCPC. 
The first step was to test the c-MycER system of JoMa 1 cells inducible by Tamoxifen. The c-MycER 
on/off switch was demonstrated by Western-Blot with the translocation of c-MycER in presence of 
Tamoxifen from cytoplasm to nucleus, where activated c-MycER is able to transactivate its target 
genes, while in absence of Tamoxifen c-MycER is inactivated in the cytoplasm. Then, the functional 
effect of the c-MycER system in JoMa 1 cells was observed by growth assay with a highly increased 
cell proliferation resulting from c-MycER activation, compared to c-MycER inactivation, as reported 
in previous study [66). Thus, the c-MycER on/off switch was highlighted at molecular and functional 
levels, which allowed us to rule out an effect of the proto-oncogene c-MycER in further in vivo tests 
performed without Tamoxifen. 
After introduction of wild-type and mutated ALK genes in JoMal cells by retroviral infection, most 
transduced JoMa 1 cells still expressed p75, which indicated that the transduction process did not 
differentiate JoMa 1 cells, and that they kept their NCPC prope1ties. Stable ALK RNA and protein 
expression were then confirmed in ALK-wt, ALK-Fl l 74L, and ALK-Rl245Q transduced cell lines. 
As NCPC, transduced JoMa 1 cells are expected to be in an undifferentiated state. In the original 
article, JoMa 1 cells were positive for the NCPC markers p75 , Slug, Sox 10 and slightly for Snail , white 
differentiation markers Mash 1, Nefü, y-actin, Calponin, Tyr, and Col2al were not detected [54). As 
observed by RT-PCR, our transduced JoMal cells expressed NCPC markers, but also smooth muscle 
and chondrocyte markers. However, that was not induced by transduction process as the parental 
JoMa 1 ce lis also expressed these markers. Sox9 is highly expressed in JoMa 1 cells , but according to 
other published reports the specificity of chondrocyte markers is controversial. ln addition to Sox9 
expression from prechondrocytic mesenchymal condensations to fully differentiated chondrocytes 
[67), it also possesses several roles in development (testes, pancreas, intestine, brain, kidney, hemt 
valves and derivatives of neural crest) and diseases (carcinomas and fibrosis-related disorders), and 
more relevant for JoMa 1 cells, Sox9 is required for formation and maintenance of neural stem ce lis in 
mouse embryogenesis and acts in specification of glial lineage [68). Thus, Sox9 seems to be a non-
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specific marker for chondrocyte differentiation. The Col2a 1 (mouse type II collagen) marker is 
expressed in chondroprogenitor cells and in chondrocytes, but also in some areas of central nervous 
system, heart and other localizations [69). Interestingly, ectopie expression of Sox9 was shown to 
induce ectopie expression of Col2a 1 [69). So the weak Col2a expression in JoMa 1 cells may be 
induced by Sox9. Thus, these chondrocyte markers are not highly specific. Nevertheles, we cannot 
exclude that a pait of JoMal cell population is initiating a smooth muscle differentiation, even in the 
presence of NCPC markers. Immunofluorescence or FACS analyses would be more adequate to 
determine the percentage of cells expressing differentiation markers. 
The influence of the expression of wild-type or mutated ALK on the differentiation potential of NCPC 
definitely needs future analyses. Especially given the previous results of orthotopic injections of 
Monc 1 cells (NCPC immortalized by constitutive v-Myc), which gave rise to 50% of tumors 
resembling chondrosarcome or osteosarcome, and 50% ofNB-like tumors, while 100% of the tumors 
driven by ALK-F J l 74L Monc 1 cells were NB-like. This could indicate a preference of the ALK gene 
to drive NB tumors, compared to the v-myc oncogene. A differentiation test of JoMa 1 cells was 
indeed performed, and results were analyzed by RT-PCR. But RT-PCR seems to not be the best 
method of analysis. Immunofluorescence should have been carried out, but could not be performed 
due to lack oftime. 
The influence of c-MycER on/off switch and ALK mutations on endogeneous c-Myc and MycN 
expressions was explored by a Real-Time PCR of their respective mRNA expression levels. The 
results showed that endogenous c-Myc mRNA was 2.5 times more abundant when c-MycER was 
activated by Tamoxifen, which confirmed a slight increase of endogenous c-Myc protein expression 
level observed by Western-Blot in presence of Tamoxifen. As the c-Myc primer used was mouse 
specific, human c-MycER should not be detected [70). Thus, the activation of c-MycER induces an 
weak increase of endogeneous c-Myc expression, which was not observed in original JoMa 1 's repmt 
where c-Myc amount was comparable with and without c-MycER activation [54) . In the absence of c-
MycER activation, ALK-F l l 74L and ALK-R l 245Q transduced cells expressed about 4 times more c-
Myc mRNA than ALK-wt and untransduced JoMal cells, which suggests an effect of constitutively 
activated ALK on endogenous c-Myc mRNA expression level. These results are in accordance with a 
study from Raetz and al. [71) showing that c-Myc is expressed in 100% of NMP/ ALK positive 
lymphoma, white c-Myc was not expressed in NMP/ALK negative lymphoma, suggesting that c-Myc 
may be a downstream target of ALK signaling. Therefore, endogenous c-Myc expression may be 
increased by ALK-Fl 174L- and ALK-Rl245Q-activating mutations, as demonstrated by NMP/ALK-
activating fusion ml,ltation. Regarding MycN mRNA expression levels in transduced JoMa 1 cells, it 
seems to be decreased when c-Myc is increased. lt has been already shown in 1989 that when MycN 
and c-Myc are co-expressed, c-Myc predominates, but the lack of c-Myc amplification allows MycN 
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expression to increase [72]. Conversely, in MycN-amplified NB, c-Myc seems to be repressed by 
MycN [73]. Thus, in JoMa 1 cells, where MycN is present but not amplified, higher levels of c-Myc 
induced by Tamoxifen or ALK mutants seem to decrease MycN expression, except in the JoMal-
ALK-F 1l74L cell line. However, it is possible that ALK-F l l 74L induces a stronger increased MycN 
expression, which counterbalances the decrease of MycN expression caused by c-Myc increase more 
efficiently than with ALK-R l 245Q. At the RNA level, ALK activation was already shown to regulate 
MycN promoter activity by increasing MycN transcriptional initiation, which could be blocked by 
specific ALK inhibitors. This somewhat explains the cooperation between ALK-F l l 74L and 
amplified MycN [74]. At the protein level, ALK-F l 174L was shown to stabilize MycN protein by 
stronger S62 phosphorylation via ERK signaling pathway, which is associated with a slightly elevated 
MycN protein level [58]. Another possible cause is that combined activation increase of Pl3K/AKT 
and RAS/ERK pathways by ALK stabilizes MycN in tumors co-expressing ALK-F l l 74L and MycN 
[75]. And indeed, AKT and ERK were shown to be more phosphorylated in transduced ALK-Fl 174L 
JoMa 1 cells than in the ALK-R l 245Q JoMa 1 cell li ne (Figure 11 ). It would therefore be interesting to 
assess the MycN protein level in JoMal transduced cells to check whether it is higher in ALK-Fl 174L 
cell line. 
Activation by phosphorylation of three ALK-signaling pathways JAK/STAT3 , PI3K/AKT, and 
RAS/MAPK was analyzed by phospho-Western-Blot. Phosphorylated ALK, which indicates ALK 
activation, was present in ALK-F l 174L and ALK-R l 245Q JoMa 1 cell lines, and weakly in ALK-wt 
JoMa 1 cells. This confirms that ALK-F l l 74L and ALK-R l 245Q mutations induce a constitutive 
activation of ALK in these NCPC. According to De Brouwer' s study [28], ALK-FI l 74L induces a 
higher level of ALK phosphorylation than ALK-Rl245Q, which was not confirmed by our phospho-
Western-Blot. ALK 140 kO isoform was weakly phosphorylated in ALK-wt JoMal cell line. A low 
activation of ALK protein by phosphorylation was already described in NB cell lines expressing ALK-
wt [28]. Moreover, Passoni and al. reported that 140 kO isoform was constitutively phosphorylated in 
highly ALK-wt expressing cells, suggesting the existence of a critical threshold for oncogenic 
activation [29]. Thus, ALK-wt JoMa 1 cell li ne could express a sufficient level of ALK-wt proteins for 
auto-activation by phosphorylation. Surprisingly, the truncated ALK 140 kD isoform was more 
phophorylated than the 220 kO isoform in wild-type as well as in mutated ALK cell lines and the 
phosphorylated 220 kO isoform was not detected in cell lines cultured in absence of Tamoxifen. The 
development of tumors without Tamoxifen suggests that the 140 kO isoform may be more essential 
for oncogenic activity than 220 kD isoform. lt would be interesting to perform phospho-Western-Blot 
on obtained tumors and compare the respective amount of phosphorylated ALK isoforms. However, in 
NB cell lines, the two isoforms were already found to be phosphorylated [29, 74]. 
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An increase in activation of the three ALK signaling pathways was expected with mutated ALK, as 
ALK is constitutively activated. Nevertheless, AKT pathways were slightly more activated in both 
mutated ALK cell lines with Tamoxifen and in ALK-F l 174L JoMa 1 cells without Tamoxifen. The 
ERK pathway was clearly more activated with ALK-F l l 74L, which may allow MycN stabilization, as 
previously mentioned. These observations contradict a previous study showing that ALK-F 1l74L 
phosphorylated STAT3 and AKT, white ALK-R1245Q phophorylated ERKl/2 and AKT in IL-3 
deprived Ba/F3 cells [ 48]. This dicrepancy may be due to a species difference. However, Berry and al. 
[75] described that ALK-FI l 74L activated PI3K/AKT and RAS/ERK pathways leading to an 
increased survival in mice, which seems to be also the case in the present study. Surprisingly, a basal 
activation of the three signaling pathways activated by phosphorylated ALK was observed in ail cell 
lines independently of ALK activation, suggesting that these pathways may be activated by others 
RTKs. It is difficult to highlight the signaling pathways activated by only one RTK such as ALK, 
because negative or positive feedbacks can modify the response in the RTK signaling network [76], 
just as the crosstalk between various RTKs can affect signaling pathways after ALK activation [77]. 
To decrease RTK activation by growth factors, cells were starved with 2.5% JoMal medium, but the 
basal activation of these signaling pathways was not reduced (data not shown). Therefore the 
activation of signaling pathways by ALK cannot be clearly distinguished from activation by other 
RTKs. 
In the in vitro assays performed to assess the growth capacity of the transduced JoMa 1 cells, the 20 
culture (growth assay) was less conclusive to distinguish wild-type and mutated ALK genes effect than 
30 culture (sphere and methylcellulose assays). But surprisingly, growth assays in unfavorable 
conditions (25% of JoMa 1 medium) resulted in higher proliferation rates than in 100% JoMa 1 
medium. This suggests that parental JoMa 1 cells proliferate better under stress conditions and that this 
reaction capacity was not affected by transduction of wild-type and mutated ALK. Alternatively, one 
or several factors in the JoMa 1 medium may act negatively to cell proliferation when present in high 
concentration. 
In sphere assays, when c-MycER was inactive, JoMa 1 cells were unable to self-renew or proliferate 
more than 2 or 3 passages, while ALK-FI 174L produced spheres up to 5 passages and ALK-R1245Q 
JoMa 1 cells up to 4 passages. ALK-F l l 74L transduced in JoMa 1 cells by Schulte and al. [3] showed 
also a maintained proliferation capacity in absence of Tamoxifen. ln addition, in two studies, these 
mutations were transduced in Ba/F3 cells. The first study showed a growth independent for IL-3 , and 
faster growth for ALK-FI 174L than ALK-Rl245Q [28] . The second showed a better cell proliferation 
in IL-3 reduced concentration for cells expressing F 1174L and R l 245Q mutation than ALK-wt or 
, · 
ALK-TI 151M. And without IL-3, only FI 174L or Rl245Q mutants survived [48]. Their resistance 
capacity may be explained in pa11 by the anti-apoptotic effect of intrinsically activated ALK [ 45] . 
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Moreover, sphere forming capacities increased at each passage in presence of active c-MycER and in 
particular for ALK-FI 174L and ALK-R1245Q JoMal cell lines. This can be explained by the 
selection of cells having higher proliferation capacity thanks to ALK constitutive activation. 
A tumorigenic assay in methylcellulose was performed as a representative assay of future in vivo tests. 
With ALK-F l l 74L and ALK-R l 245Q cell lines, we observed an increased number of large colonies 
with c-MycER activation, white in the absence of c-MycER activation the difference with control cells 
was not significative. The c-MycER activity may be required to stimulate 30 growth in this semi-sol id 
medium, and ALK mutations are not able to compensate the absence of c-MycER. Oespite that, 
constitutive activation of ALK in JoMa 1 cells seems to give an advantage in 30 growth. This is in 
accordance with a previous study showing that NIH3T3 transfected with ALK-F l l 74L, K 1062M, and 
the protein fusion EML4-ALK also displayed an increase in colony formation in soft agar compared to 
ALK-wt [30]. 
A first in vivo assay was performed by subcutaneous implantations of ALK-wt, ALK mutants (FI 174L 
and R l 254Q) and controls (parental JoMa 1 and JoMa 1 ce lis transduced with vector pMigr) in nude 
mice. Mice injected with ALK-FI 174L JoMal cells were the first to present tumors followed by ALK-
R 1245Q and then ALK-wt groups. That was not surprising, as ALK-F 1174 had already been indicated 
to display a higher transforming capacity compared to ALK-R l 245Q [28, 74, 78]. 100% tumor take 
was observed in ALK-F 1 l 74L and ALK-R l 245Q groups as 6/6 injected sites developed tumors, 
compared to 416 for ALK-wt group. Interestingly, ALK-wt displayed a tumorigenic capacity in vivo, 
even if weaker than ALK mutants, despite the fact that in vitro in methylcellulose assay, ALK-wt did 
not show increased tumorigenic ability compared to controls. The tumorigenic capacity of ALK 
mutants in vivo was already explored by Schulte and al. [3] who also injected subcutaneously JoMal 
cells transfected with ALK-F l 174L in nude mice, but they obtained tumor formation in only 2/6 mi ce. 
Chen and al. [30] transfected NIH3T3 fibroblasts with wild-type ALK and mutants (F l 174L, K 1062M 
and EML4-ALK), which were then injected subcutaneously in nude mice. They obtained 100% of 
tumorigenesis with mutants but nothing with wild-type ALK. However, an oncogenic effect of ALK-
wt had already been reported by Passoni and al. [29] with an ALK constitutive activation and an 
aberrant ALK phosphorylation in IMR-32 cells, an NB cell line expressing ALK-wt. They also 
demonstrated that inhibition of ALK in NB cells overexpressing wild-type or mutated ALK induced 
growth arrest and cell death. In addition, a greater proportion of ALK overexpressing NB was shown 
to be present in unfavorable stages than in localized stages. They concluded that ALK-wt possess a 
threshold of expression to achieve an oncogenic effect and that other mechanisms than mutation or 
amplification regulate ALK expression level. Thus, incomplete tumorigenic capacity of ALK-wt in 
our subcutaneous assays can be explained by ALK-wt expression variation, with a threshold of 
expression needed to achieve tumorigenicity that was not systematically attained. In the future it 
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would be interesting to analyze ALK activation level in ALK-wt derived tumors to determine whether 
they increased constitutive activation during tumorigenesis. The negative controls JoMal and JoMal-
Migr did not present any tumors, which ruled out an influence of the pMigr vector in tumorigenesis, or 
a rote of c-mycER. Most importantly, as tumors grew only in wild-type and mutated ALK groups, the 
ALK expression in NCPC seems to play an essential rote in tumor initiation. 
The next step was to characterize these tumors. Thus, RT-PCR and immunohistochemistry were 
performed on subcutaneous tumors of wild-type and mutated ALK groups to distinguish JoMal cells 
proliferation from NB or other tumor type formation. As observed by RT-PCR, ail tumors expressed 
NCSC markers, but also smooth muscle and chondrocyte markers, which was not surprising as 
transduced JoMal cells were already expressing these markers before subcutaneous injections. P75, 
used here as an NCSC marker, was described to be present in differentiated NB and absent in poorly 
differentiated NB [79]. The other NCSC marker, Slug, was also detected in NB cell lines [80] . 
Concerning smooth muscle markers, requiring vessels to feed cells, tumors may contain some 
arterioles or venules containing smooth muscle. Most tumors expressed neuronal markers, which did 
not exclude NB tumor type, because Mash 1 was shown to be highly expressed in NB [81 ], tumors can 
be innerved and NB is a neuro-endocrine tumor. One ALK-R 1245Q tumor was positive for the 
melanocyte marker, which can be due to a subcutaneous cell environment possibly promoting this 
means of differentiation or perhaps some subcutaneous cells were also removed during dissection. 
Only one ALK-wt tumor expressed Phox2b, an NB marker. Phox2b plays an important rote in the 
differentiation of autonomie neurons [82], and is expressed in some cells of the autonomie nervous 
system as neurons of sympathetic ganglia or chromaffin cells of adrenal medulla [83]. ln addition 
Phox2b mRNA was shown to be nearly always elevated in neuroblastic tumors and to be a highly 
sensitive and specific NB marker by IHC in pediatric smalt round blue-cell tumors [83]. 
The histo-pathology of subcutaneous tumors was compatible with NB-like tumors in cell type and 
morphology. The others NB-like tumors, such as melanoma and Ewing's sarcoma, were ruled out by 
IHC markers. Nevertheless, these results need to be completed with NB markers, such as TH or 
Synaptophysin, but the specificity of NB markers appears to be different in mice and humans. For 
example, the presence of C044 in human NB was shown to be a good prognostic factor [84]. But 
interestingly, Valentiner and al. reported that expression of C044 in human NB cells injected 
subcutaneously in mice was associated with metastatic pattern [85], suggesting an opposite prognostic 
value of C044 in mice and humans. Although the specificity of these markers in mi ce is debatable, we 
don ' t possess a lot of tools to characterize NB. Thus, even if RT-PCR did not allow a clear tumor 
characterization, except for one wild-type tumor expressing Phox2b, NB tumor type was not excluded. 
, · 
Histology Jeans towards for NB tumor and analyses should be completed with other NB markers. 
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Transduced JoMa 1 cells were 01thotopically implanted into the adrenal gland of nude mice. This 
orthotopic NB mode! was demonstrated to faithfully reproduce the clinical appearance of human NB 
[62]. lndeed, orthotopic implantation of cells allows interaction with the microenvironment, which is 
known to play an impo1tant role in regulation of stem cell fate [86] and in tumorigenesis by interaction 
of microenvironment with tumor stem cells [87]. So it was important to analyze the tumorigenic 
capacity of ALK-wt and mutants in the natural NB microenvironment. 01thotopic injections 
confirmed the growth results obtained in subcutaneous injections. lndeed, mice injected with ALK-
F 1174L JoMal cells already presented tumors after 24 days and needed to be sacrificed early followed 
by mice bearing ALK-R1245Q and ALK-wt JoMal cells. Tumor take was incomplete for ALK-wt 
group, as previously observed in subcutaneous injection. The main differences between subcutaneous 
and 01thotopic injections were that in 01thotopic groups, tumors appeared in several different sites 
(adrenal gland, abdomen, spleen, kidney, and stomach) and the tumor take of ALK-Fl l 74L group was 
not 100% in 01thotopic conditions as 1/6 mice did not develop any tumors. Surprisingly, dissemination 
sites (kidney, spleen, abdomen, and stomach) were not typical anatomie sites for NB metastasis and 
some mice developed only abdominal tumors. ln the orthotopic NB mode! developed by Joseph and 
al. [62] , mice did not present tumors in sites other than bone marrow and Iiver, which are sites of 
human NB metastasis due to hematologic dissemination [62]. However, in transgenic mice co-
expresssing ALK-F l 174L and MycN, Berry and al. [75] also obtained abnormal dissemination sites 
("thoracic and abdominal masses that arose in the paraspinal ganglia and adrenals" but also "focal 
masses on the forelimb, neck and shoulder"). Thus, in future analyses, it will be interesting to assay 
whether abdominal and adrenal tumors are both NB-Iike tumors. If NCPC transduced with wild-type 
or mutated ALK are able to induce NB formation in the abdominal cavity, this would suggest that 
microenvironment is not essential in NB differentiation and that the ALK gene can be sufficient for NB 
tumorigenesis, regardless of anatomie Iocalization. ln addition, the NB metastasis development in our 
mice may be in part impaired by fast tumoral growth. 
ln 2012, while this study was ongoing, two repo1ts were published on ALK-FI 174L and MycN 
implication in NB initiation, both using transgenic mice [58, 75]. ln Heukamp's study [58], mice 
expressing ALK-F l l 74L in neural crest derivatives were created. Among these transgenic mice, 5/12 
mice developed tumors in retroperitoneal or neck regions between 130 and 351 days of age. Two mice 
also presented hepatic metastasis, and another a mediastinal Iesion. They explained the incomplete 
penetrance and the relatively long time frame required for tumor development by the necessity of a 
second genetic event to occur. lndeed, clu·omosomic aberrations were observed in these tumors, that 
corresponded syntenically to the aberrations usually found in human NB (q 1 gain, 17 gain, MycN 
amplification). But in tumors from mice expressing both ALK-F 1174L and MycN by transgenic 
process, chromosomal aberrations were reduced, as if both abnormalities were sufficient to drive NB 
initiation. That can be explained by the two-hit hypothesis of Alfred G. Knudson, where two mutations 
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are generally necessary to induce a tumor [88]. MycN overexpression and ALK mutation are two 
possible hits able to drive NB tumor genesis. Given these results it would be interesting to analyse if 
our tumors express other chromosomal aberrations. ln Berry ' s study [75], transgenic mice expressing 
ALK-F l l 74L and ALK-wt in neural crest cells did not develop tumor. But all transgenic mice co-
expressing ALK-F 1l74L and MycN amplification had to be sacrificed due to tumor growth. These 
two studies demonstrated the synergy between ALK-F l l 74L and MycN amplification for driving NB, 
but only Heukamp's study showed the capacity of ALK-Fl 174L to drive neuroblastomagenesis alone. 
The discrepancy between these two studies may be due to the different expression levels of ALK in 
transgenic mice, as different promoters were used to drive ALK expression in each transgenic mode!. 
The ability of ALK-wt to drive tumorigenicity in our JoMal cells may be due to its high expression 
level , which may be sufficient for its constitutive activation, as previously discussed. 
Therefore, our study brings additional results confirming the ALK-F l 174L tumorigenic capacity from 
NCPC in an orthotopic mode! , and demonstrates for the first time that ALK-wt and ALK-Rl245Q are 
also able to drive NB initiation from NCPC. Moreover, tumors grew in absence of Tamoxifen which 
rules out the participation of c-MycER activation in tumorigenesis. 
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Conclusion and perspectives 
ALK mutations, amplification and overexpression have been described in a subset of NB. As already 
shown in previous studies, we confirm that ALK-Fl l 74L has a stronger tumorigenic capacity than 
ALK-R l 245Q, and that both express ALK constitutive activation and possess tumorigenic prop1ties in 
vitro . In vivo, we demonstrated that expression of ALK-FI 174L is sufficient to induce tumor 
formation from neural crest progenitor cells in an 01thotopic model of NB, and for the first time that 
ALK-wt or ALK-Rl245Q are also able to induce tumorigenesis. 
The next step of the project will be to analyze obtained orthotopic tumor types to confirm that wild-
type and mutated ALK drive neuroblastomagenesis from NCPC. Given the difficulty of classifying 
tumor type in subcutaneous tumors, we intend to perform transcriptomic profiling of 01thotopic 
tumors, and to compare results using the NB-specific database of the Curie Institut of Paris. Tumor 
histology will also be analyzed for NB markers using H&E and IHC. With the results of 
transcriptomic profiles, others genomic expression aberrations can be identified allowing to highlight a 
possible second hit in tumorignesis or deregulation of gene expression important for tumorigenicity. ln 
addition, difference in gene expression profiles between the 01thotopic tumors derived from JoMa 1-
ALK-wt, -ALK-F, or -ALK-R cells may be identified through this analysis. 
Orthotopic tumors were dissociated and tumoral JoMal cells were cultured in vitro to determine 
whether tumoral transformation results in new prope1ties. lndeed, ALK inhibitor resistance could be 
assayed on these cells to test whether they are sensitive to this therapy or if they acquired 
independence from ALK oncogenic activity. 
lt will be also interesting to analyze ALK expression and activation by phospho-Western-Blot in 
tumors, as a potential correlation between constitutive activation and high ALK expression had been 
repo1ted by Passoni and al. [29] in ALK-wt tumors. Moreover the phosphorylated state of ALK 
isoforms could indiate whether one of them is more important for tumorigenesis Also, the analyses of 
signaling pathways activation in ail tumor groups could indicate whether a pathway is essential for 
tumor growth or ifthe activation profile is different in tumors driven by ALK-FI 174L, ALK-Rl245Q, 
or ALK-wt. Regarding RTK expression, as ALK signaling pathways are probably also activated by 
other RTKs and a crosstalk between different RTKs was described in cancer [77], perhaps a putative 
correlation between ALK and Trk should be studied. 
Given our dissemination sites in the 01thotopic model , it could be interesting to inject fewer cells in 
the adrenal gland in future orthotopic experiments to allow more time for metastatic dissemination, or 
to inject cells in blood circulation to highlight a possible chemotropism of NCPC for sympathetic 
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nervous system tissues or others sites. ln addition, ALK inhibitor use on mice presenting adrenal 
tumors after orthotopic injection would allow confirmation of the importance of ALK expression in 
tumorigenesis. 01thotopic implantation with mice treated with Tamoxifen could also highlight a 
potential cooperation of c-Myc and ALK in tumorigenesis. 
, . 
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